Entrez un mot ou une phrase dans n'importe quelle langue 👆
Langue:
Traduction et analyse de mots par intelligence artificielle ChatGPT
Sur cette page, vous pouvez obtenir une analyse détaillée d'un mot ou d'une phrase, réalisée à l'aide de la meilleure technologie d'intelligence artificielle à ce jour:
- comment le mot est utilisé
- fréquence d'utilisation
- il est utilisé plus souvent dans le discours oral ou écrit
- options de traduction de mots
- exemples d'utilisation (plusieurs phrases avec traduction)
- étymologie
Qu'est-ce (qui) est EML4-ALK positive lung cancer - définition
EML4-ALK positive lung cancer
TYPE OF CANCER
ELM4-ALK positive lung cancer; EML4-ALK positive lung cancer
EML4-ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. This abnormal gene fusion leads to the production of a protein (EML4-ALK) that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells.
ALK
WIKIMEDIA DISAMBIGUATION PAGE
Alk; ALK (disambiguation)
Automatisierte LiegenschaftsKarte (Reference: ALTIS)
Non-small-cell lung carcinoma
![programmed death receptor 1]] (PD-1) expressed on the surface of T cells, and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a monoclonal antibody that targets Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of T cells. Bevacizumab is a monoclonal antibody that targets Vascular Endothelial Growth Factor (VEGF) in the circulation and functions as an angiogenesis inhibitor.<ref name="Nasser Gorenberg 2020"/>](https://commons.wikimedia.org/wiki/Special:FilePath/Monoclonal antibodies used in the treatment of non small cell lung cancer and their mechanism of action.webp?width=200 "programmed death receptor 1]] (PD-1) expressed on the surface of T cells, and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a monoclonal antibody that targets Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of T cells. Bevacizumab is a monoclonal antibody that targets Vascular Endothelial Growth Factor (VEGF) in the circulation and functions as an angiogenesis inhibitor.<ref name=\"Nasser Gorenberg 2020\"/>")
![50px]] Text was copied from this source, which is available under a [https://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International License].</ref>](https://commons.wikimedia.org/wiki/Special:FilePath/Pharmaceuticals-13-00373-g002-550.jpg?width=200 "50px]] Text was copied from this source, which is available under a [https://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International License].</ref>")
ANY TYPE OF EPITHELIAL LUNG CANCER OTHER THAN SMALL-CELL LUNG CARCINOMA
Non-small cell lung cancer; NSCLC; Non-small cell lung cancer staging; Carcinoma, non-small-cell lung; Non-small cell lung carcinoma staging; Squamous cell lung cancer; Non-small cell lung carcinoma; Non-small-cell lung carcinoma staging; Non small cell lung carcinoma; Squamous cell carcinoma of lung; Non-Small Cell Lung Cancer; Non-small cell lung carcinomas; Non small-cell lung carcinoma; Non small-cell lung cancer; Non-small cell carcinoma; Non-small-cell lung carcinoma
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
